Voyager Therapeutics (NASDAQ:VYGR) Earns "Buy" Rating from HC Wainwright

Key Points

• HC Wainwright has reiterated a Buy rating for Voyager Therapeutics (NASDAQ:VYGR) with a target price of $30.00.
• Despite the positive outlook from HC Wainwright, Wedbush has lowered its target price for the stock from $9.00 to $8.00, with an "outperform" rating.
• Voyager Therapeutics is currently trading at $4.18 and reported a quarterly EPS of ($0.57), missing estimates.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report)'s stock had its "buy" rating restated by equities researchers at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $30.00 price objective on the stock.

Separately, Wedbush reduced their price target on Voyager Therapeutics from $9.00 to $8.00 and set an "outperform" rating for the company in a research report on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating and seven have given a Buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $13.25.

Voyager Therapeutics Price Performance

Voyager Therapeutics stock traded down $0.25 during mid-day trading on Monday, hitting $4.25. The company's stock had a trading volume of 469,922 shares, compared to its average volume of 548,102. The company has a market cap of $235.47 million, a PE ratio of -2.30 and a beta of 0.90. Voyager Therapeutics has a 52-week low of $2.64 and a 52-week high of $8.27. The firm's 50 day moving average is $3.55 and its 200 day moving average is $3.43.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.09). The firm had revenue of $5.20 million during the quarter, compared to analyst estimates of $9.50 million. Voyager Therapeutics had a negative net margin of 253.49% and a negative return on equity of 37.65%. As a group, analysts forecast that Voyager Therapeutics will post -0.91 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in VYGR. Cubist Systematic Strategies LLC bought a new stake in Voyager Therapeutics in the 4th quarter worth about $29,000. CWM LLC increased its stake in shares of Voyager Therapeutics by 856.3% in the first quarter. CWM LLC now owns 10,471 shares of the company's stock worth $35,000 after buying an additional 9,376 shares during the period. Bank of Montreal Can purchased a new position in Voyager Therapeutics during the 2nd quarter valued at about $36,000. R Squared Ltd bought a new stake in Voyager Therapeutics during the 2nd quarter valued at approximately $48,000. Finally, Los Angeles Capital Management LLC bought a new position in Voyager Therapeutics during the second quarter valued at approximately $50,000. 48.03% of the stock is owned by institutional investors.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.